Last reviewed · How we verify

ACT guided Routine Treatment

GlaxoSmithKline · FDA-approved active Small molecule

ACT guided Routine Treatment is a clinical management strategy that uses Artemisinin-based Combination Therapy (ACT) with routine diagnostic testing to optimize malaria treatment outcomes.

ACT guided Routine Treatment is a treatment strategy that uses Artemisinin-based Combination Therapy (ACT) guided by diagnostic testing to optimize malaria treatment outcomes. Used for Malaria (uncomplicated and severe forms, guided by diagnostic confirmation).

At a glance

Generic nameACT guided Routine Treatment
SponsorGlaxoSmithKline
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

This is a treatment protocol rather than a single drug entity, combining artemisinin-based antimalarial combinations with systematic diagnostic guidance to ensure appropriate patient selection and dosing. The approach aims to improve treatment efficacy, reduce drug resistance, and minimize unnecessary antimalarial use through evidence-based routine testing protocols.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: